68Ga-NOTA-Aca-BBN(7-14) PET imaging of GRPR in children with optic pathway glioma
Purpose Optic pathway glioma (OPG) is a rare neoplasm that arises predominantly during childhood. Its location in a sensitive region involving the optic pathways, onset in young patients and controversial therapy choice make the management of OPG a challenge in paediatric neuro-oncology. In this stu...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2019-09, Vol.46 (10), p.2152-2162 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2162 |
|---|---|
| container_issue | 10 |
| container_start_page | 2152 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 46 |
| creator | Zhang, Jingjing Tian, Yongji Li, Deling Niu, Gang Lang, Lixin Li, Fang Liu, Yuhan Zhu, Zhaohui Chen, Xiaoyuan |
| description | Purpose
Optic pathway glioma (OPG) is a rare neoplasm that arises predominantly during childhood. Its location in a sensitive region involving the optic pathways, onset in young patients and controversial therapy choice make the management of OPG a challenge in paediatric neuro-oncology. In this study we assessed gastrin-releasing peptide receptor (GRPR)-targeted positron emission tomography (PET) imaging in children with OPG, and the application of a PET/MRI imaging-guided surgery navigation platform.
Methods
Eight children (five boys, mean age 8.81 years, range 5–14 years) with suspicion of optic pathway glioma on MRI were recruited. Written informed consent was obtained from all patients and legal guardians. Brain PET/CT or PET/MRI acquisitions were performed 30 min after intravenous injection of 1.85 MBq/kg body weight of
68
Ga-NOTA-Aca-BBN(7-14). Four patients also underwent
18
F-FDG brain PET/CT for comparison. All patients underwent surgical resection within 1 week.
Results
All 11 lesions (100%) in the eight patients showed prominent
68
Ga-NOTA-Aca-BBN(7-14) uptake with excellent contrast in relation to surrounding normal brain tissue. Tumour-to-background ratios (SUVmax and SUVmean) were significantly higher for
68
Ga-NOTA-Aca-BBN(7-14) than for
18
F-FDG (28.4 ± 5.59 vs. 0.47 ± 0.11 and 18.3 ± 4.99 vs. 0.35 ± 0.07, respectively). Fusion images for tumour delineation were obtained in all patients using the PET/MRI navigation platform. All lesions were pathologically confirmed as OPGs with positive GRPR expression, and 75% were pilocytic astrocytoma WHO grade I and 25% were diffuse astrocytoma WHO grade II. There was a positive correlation between the SUV of
68
Ga-NOTA-Aca-BBN(7-14) and the expression level of GRPR (
r
2
= 0.56,
P
|
| doi_str_mv | 10.1007/s00259-019-04392-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2251465571</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2251465571</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1977-7d0db908cc922f870e2a71ebafe35cf91c1b31b2e4ca1e1b5cf706a6d093b853</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EEqXwA6wssYGFYcZ5OF62VSlIqC1V9pbjOGmqNglOq6p_jyEIdixG89C9M5pDyC3CIwKIpw6AR5IB-ggDyZk4IwOMfSsgkee_tYBLctV1GwBMeCIH5D1OZprNF-mIjYxm4_H8XjAMH-hymtJqp8uqLmlT0NlquaJVTc262ubO1vRY7de0afeVoa3er4_6RMtt1ez0Nbko9LazNz95SNLnaTp5YW-L2etk9MYMSiGYyCHPJCTGSM6LRIDlWqDNdGGDyBQSDWYBZtyGRqPFzM8ExDrOQQZZEgVDctevbV3zcbDdXm2ag6v9RcV5hGEcRQK9ivcq45quc7ZQrfNfuZNCUF_kVE9OeXLqm5wS3hT0ps6L69K6v9X_uD4BqeJtlQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2251465571</pqid></control><display><type>article</type><title>68Ga-NOTA-Aca-BBN(7-14) PET imaging of GRPR in children with optic pathway glioma</title><source>Springer Nature - Complete Springer Journals</source><creator>Zhang, Jingjing ; Tian, Yongji ; Li, Deling ; Niu, Gang ; Lang, Lixin ; Li, Fang ; Liu, Yuhan ; Zhu, Zhaohui ; Chen, Xiaoyuan</creator><creatorcontrib>Zhang, Jingjing ; Tian, Yongji ; Li, Deling ; Niu, Gang ; Lang, Lixin ; Li, Fang ; Liu, Yuhan ; Zhu, Zhaohui ; Chen, Xiaoyuan</creatorcontrib><description>Purpose
Optic pathway glioma (OPG) is a rare neoplasm that arises predominantly during childhood. Its location in a sensitive region involving the optic pathways, onset in young patients and controversial therapy choice make the management of OPG a challenge in paediatric neuro-oncology. In this study we assessed gastrin-releasing peptide receptor (GRPR)-targeted positron emission tomography (PET) imaging in children with OPG, and the application of a PET/MRI imaging-guided surgery navigation platform.
Methods
Eight children (five boys, mean age 8.81 years, range 5–14 years) with suspicion of optic pathway glioma on MRI were recruited. Written informed consent was obtained from all patients and legal guardians. Brain PET/CT or PET/MRI acquisitions were performed 30 min after intravenous injection of 1.85 MBq/kg body weight of
68
Ga-NOTA-Aca-BBN(7-14). Four patients also underwent
18
F-FDG brain PET/CT for comparison. All patients underwent surgical resection within 1 week.
Results
All 11 lesions (100%) in the eight patients showed prominent
68
Ga-NOTA-Aca-BBN(7-14) uptake with excellent contrast in relation to surrounding normal brain tissue. Tumour-to-background ratios (SUVmax and SUVmean) were significantly higher for
68
Ga-NOTA-Aca-BBN(7-14) than for
18
F-FDG (28.4 ± 5.59 vs. 0.47 ± 0.11 and 18.3 ± 4.99 vs. 0.35 ± 0.07, respectively). Fusion images for tumour delineation were obtained in all patients using the PET/MRI navigation platform. All lesions were pathologically confirmed as OPGs with positive GRPR expression, and 75% were pilocytic astrocytoma WHO grade I and 25% were diffuse astrocytoma WHO grade II. There was a positive correlation between the SUV of
68
Ga-NOTA-Aca-BBN(7-14) and the expression level of GRPR (
r
2
= 0.56,
P
< 0.01, for SUVmax;
r
2
= 0.47,
P
< 0.05, for SUVmean).
Conclusion
This prospective study showed the feasibility of
68
Ga-NOTA-Aca-BBN(7-14) PET in children with OPG for tumour detection and localization.
68
Ga-NOTA-Aca-BBN(7-14) PET/MRI may be helpful for assisting surgery planning in OPG patients with severe symptoms, GRPR-targeted PET has the potential to provide imaging guidance for further GRPR-targeted therapy in patients with OPG.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-019-04392-7</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Astrocytoma ; Body weight ; Brain ; Brain tumors ; Cardiology ; Children ; Computed tomography ; Emission analysis ; Feasibility studies ; Fluorine isotopes ; Gastrin ; Gastrin-releasing peptide ; Glioma ; Imaging ; Infection and inflammation ; Informed consent ; Intravenous administration ; Lesions ; Localization ; Magnetic resonance imaging ; Medical imaging ; Medicine ; Medicine & Public Health ; Neoplasia ; Neuroimaging ; Nuclear Medicine ; Oncology ; Original Article ; Orthopedics ; Positron emission ; Positron emission tomography ; Radiology ; Signs and symptoms ; Surgery ; Therapy ; Tomography ; Tumors ; Visual pathways</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2019-09, Vol.46 (10), p.2152-2162</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2019</rights><rights>European Journal of Nuclear Medicine and Molecular Imaging is a copyright of Springer, (2019). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1977-7d0db908cc922f870e2a71ebafe35cf91c1b31b2e4ca1e1b5cf706a6d093b853</citedby><cites>FETCH-LOGICAL-c1977-7d0db908cc922f870e2a71ebafe35cf91c1b31b2e4ca1e1b5cf706a6d093b853</cites><orcidid>0000-0002-9622-0870</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00259-019-04392-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00259-019-04392-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Zhang, Jingjing</creatorcontrib><creatorcontrib>Tian, Yongji</creatorcontrib><creatorcontrib>Li, Deling</creatorcontrib><creatorcontrib>Niu, Gang</creatorcontrib><creatorcontrib>Lang, Lixin</creatorcontrib><creatorcontrib>Li, Fang</creatorcontrib><creatorcontrib>Liu, Yuhan</creatorcontrib><creatorcontrib>Zhu, Zhaohui</creatorcontrib><creatorcontrib>Chen, Xiaoyuan</creatorcontrib><title>68Ga-NOTA-Aca-BBN(7-14) PET imaging of GRPR in children with optic pathway glioma</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Purpose
Optic pathway glioma (OPG) is a rare neoplasm that arises predominantly during childhood. Its location in a sensitive region involving the optic pathways, onset in young patients and controversial therapy choice make the management of OPG a challenge in paediatric neuro-oncology. In this study we assessed gastrin-releasing peptide receptor (GRPR)-targeted positron emission tomography (PET) imaging in children with OPG, and the application of a PET/MRI imaging-guided surgery navigation platform.
Methods
Eight children (five boys, mean age 8.81 years, range 5–14 years) with suspicion of optic pathway glioma on MRI were recruited. Written informed consent was obtained from all patients and legal guardians. Brain PET/CT or PET/MRI acquisitions were performed 30 min after intravenous injection of 1.85 MBq/kg body weight of
68
Ga-NOTA-Aca-BBN(7-14). Four patients also underwent
18
F-FDG brain PET/CT for comparison. All patients underwent surgical resection within 1 week.
Results
All 11 lesions (100%) in the eight patients showed prominent
68
Ga-NOTA-Aca-BBN(7-14) uptake with excellent contrast in relation to surrounding normal brain tissue. Tumour-to-background ratios (SUVmax and SUVmean) were significantly higher for
68
Ga-NOTA-Aca-BBN(7-14) than for
18
F-FDG (28.4 ± 5.59 vs. 0.47 ± 0.11 and 18.3 ± 4.99 vs. 0.35 ± 0.07, respectively). Fusion images for tumour delineation were obtained in all patients using the PET/MRI navigation platform. All lesions were pathologically confirmed as OPGs with positive GRPR expression, and 75% were pilocytic astrocytoma WHO grade I and 25% were diffuse astrocytoma WHO grade II. There was a positive correlation between the SUV of
68
Ga-NOTA-Aca-BBN(7-14) and the expression level of GRPR (
r
2
= 0.56,
P
< 0.01, for SUVmax;
r
2
= 0.47,
P
< 0.05, for SUVmean).
Conclusion
This prospective study showed the feasibility of
68
Ga-NOTA-Aca-BBN(7-14) PET in children with OPG for tumour detection and localization.
68
Ga-NOTA-Aca-BBN(7-14) PET/MRI may be helpful for assisting surgery planning in OPG patients with severe symptoms, GRPR-targeted PET has the potential to provide imaging guidance for further GRPR-targeted therapy in patients with OPG.</description><subject>Astrocytoma</subject><subject>Body weight</subject><subject>Brain</subject><subject>Brain tumors</subject><subject>Cardiology</subject><subject>Children</subject><subject>Computed tomography</subject><subject>Emission analysis</subject><subject>Feasibility studies</subject><subject>Fluorine isotopes</subject><subject>Gastrin</subject><subject>Gastrin-releasing peptide</subject><subject>Glioma</subject><subject>Imaging</subject><subject>Infection and inflammation</subject><subject>Informed consent</subject><subject>Intravenous administration</subject><subject>Lesions</subject><subject>Localization</subject><subject>Magnetic resonance imaging</subject><subject>Medical imaging</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasia</subject><subject>Neuroimaging</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Radiology</subject><subject>Signs and symptoms</subject><subject>Surgery</subject><subject>Therapy</subject><subject>Tomography</subject><subject>Tumors</subject><subject>Visual pathways</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp9kMtOwzAQRS0EEqXwA6wssYGFYcZ5OF62VSlIqC1V9pbjOGmqNglOq6p_jyEIdixG89C9M5pDyC3CIwKIpw6AR5IB-ggDyZk4IwOMfSsgkee_tYBLctV1GwBMeCIH5D1OZprNF-mIjYxm4_H8XjAMH-hymtJqp8uqLmlT0NlquaJVTc262ubO1vRY7de0afeVoa3er4_6RMtt1ez0Nbko9LazNz95SNLnaTp5YW-L2etk9MYMSiGYyCHPJCTGSM6LRIDlWqDNdGGDyBQSDWYBZtyGRqPFzM8ExDrOQQZZEgVDctevbV3zcbDdXm2ag6v9RcV5hGEcRQK9ivcq45quc7ZQrfNfuZNCUF_kVE9OeXLqm5wS3hT0ps6L69K6v9X_uD4BqeJtlQ</recordid><startdate>20190901</startdate><enddate>20190901</enddate><creator>Zhang, Jingjing</creator><creator>Tian, Yongji</creator><creator>Li, Deling</creator><creator>Niu, Gang</creator><creator>Lang, Lixin</creator><creator>Li, Fang</creator><creator>Liu, Yuhan</creator><creator>Zhu, Zhaohui</creator><creator>Chen, Xiaoyuan</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><orcidid>https://orcid.org/0000-0002-9622-0870</orcidid></search><sort><creationdate>20190901</creationdate><title>68Ga-NOTA-Aca-BBN(7-14) PET imaging of GRPR in children with optic pathway glioma</title><author>Zhang, Jingjing ; Tian, Yongji ; Li, Deling ; Niu, Gang ; Lang, Lixin ; Li, Fang ; Liu, Yuhan ; Zhu, Zhaohui ; Chen, Xiaoyuan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1977-7d0db908cc922f870e2a71ebafe35cf91c1b31b2e4ca1e1b5cf706a6d093b853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Astrocytoma</topic><topic>Body weight</topic><topic>Brain</topic><topic>Brain tumors</topic><topic>Cardiology</topic><topic>Children</topic><topic>Computed tomography</topic><topic>Emission analysis</topic><topic>Feasibility studies</topic><topic>Fluorine isotopes</topic><topic>Gastrin</topic><topic>Gastrin-releasing peptide</topic><topic>Glioma</topic><topic>Imaging</topic><topic>Infection and inflammation</topic><topic>Informed consent</topic><topic>Intravenous administration</topic><topic>Lesions</topic><topic>Localization</topic><topic>Magnetic resonance imaging</topic><topic>Medical imaging</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasia</topic><topic>Neuroimaging</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Radiology</topic><topic>Signs and symptoms</topic><topic>Surgery</topic><topic>Therapy</topic><topic>Tomography</topic><topic>Tumors</topic><topic>Visual pathways</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Jingjing</creatorcontrib><creatorcontrib>Tian, Yongji</creatorcontrib><creatorcontrib>Li, Deling</creatorcontrib><creatorcontrib>Niu, Gang</creatorcontrib><creatorcontrib>Lang, Lixin</creatorcontrib><creatorcontrib>Li, Fang</creatorcontrib><creatorcontrib>Liu, Yuhan</creatorcontrib><creatorcontrib>Zhu, Zhaohui</creatorcontrib><creatorcontrib>Chen, Xiaoyuan</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Neurosciences Abstracts</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Database (1962 - current)</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest advanced technologies & aerospace journals</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Jingjing</au><au>Tian, Yongji</au><au>Li, Deling</au><au>Niu, Gang</au><au>Lang, Lixin</au><au>Li, Fang</au><au>Liu, Yuhan</au><au>Zhu, Zhaohui</au><au>Chen, Xiaoyuan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>68Ga-NOTA-Aca-BBN(7-14) PET imaging of GRPR in children with optic pathway glioma</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><date>2019-09-01</date><risdate>2019</risdate><volume>46</volume><issue>10</issue><spage>2152</spage><epage>2162</epage><pages>2152-2162</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>Purpose
Optic pathway glioma (OPG) is a rare neoplasm that arises predominantly during childhood. Its location in a sensitive region involving the optic pathways, onset in young patients and controversial therapy choice make the management of OPG a challenge in paediatric neuro-oncology. In this study we assessed gastrin-releasing peptide receptor (GRPR)-targeted positron emission tomography (PET) imaging in children with OPG, and the application of a PET/MRI imaging-guided surgery navigation platform.
Methods
Eight children (five boys, mean age 8.81 years, range 5–14 years) with suspicion of optic pathway glioma on MRI were recruited. Written informed consent was obtained from all patients and legal guardians. Brain PET/CT or PET/MRI acquisitions were performed 30 min after intravenous injection of 1.85 MBq/kg body weight of
68
Ga-NOTA-Aca-BBN(7-14). Four patients also underwent
18
F-FDG brain PET/CT for comparison. All patients underwent surgical resection within 1 week.
Results
All 11 lesions (100%) in the eight patients showed prominent
68
Ga-NOTA-Aca-BBN(7-14) uptake with excellent contrast in relation to surrounding normal brain tissue. Tumour-to-background ratios (SUVmax and SUVmean) were significantly higher for
68
Ga-NOTA-Aca-BBN(7-14) than for
18
F-FDG (28.4 ± 5.59 vs. 0.47 ± 0.11 and 18.3 ± 4.99 vs. 0.35 ± 0.07, respectively). Fusion images for tumour delineation were obtained in all patients using the PET/MRI navigation platform. All lesions were pathologically confirmed as OPGs with positive GRPR expression, and 75% were pilocytic astrocytoma WHO grade I and 25% were diffuse astrocytoma WHO grade II. There was a positive correlation between the SUV of
68
Ga-NOTA-Aca-BBN(7-14) and the expression level of GRPR (
r
2
= 0.56,
P
< 0.01, for SUVmax;
r
2
= 0.47,
P
< 0.05, for SUVmean).
Conclusion
This prospective study showed the feasibility of
68
Ga-NOTA-Aca-BBN(7-14) PET in children with OPG for tumour detection and localization.
68
Ga-NOTA-Aca-BBN(7-14) PET/MRI may be helpful for assisting surgery planning in OPG patients with severe symptoms, GRPR-targeted PET has the potential to provide imaging guidance for further GRPR-targeted therapy in patients with OPG.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><doi>10.1007/s00259-019-04392-7</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-9622-0870</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2019-09, Vol.46 (10), p.2152-2162 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_proquest_journals_2251465571 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Astrocytoma Body weight Brain Brain tumors Cardiology Children Computed tomography Emission analysis Feasibility studies Fluorine isotopes Gastrin Gastrin-releasing peptide Glioma Imaging Infection and inflammation Informed consent Intravenous administration Lesions Localization Magnetic resonance imaging Medical imaging Medicine Medicine & Public Health Neoplasia Neuroimaging Nuclear Medicine Oncology Original Article Orthopedics Positron emission Positron emission tomography Radiology Signs and symptoms Surgery Therapy Tomography Tumors Visual pathways |
| title | 68Ga-NOTA-Aca-BBN(7-14) PET imaging of GRPR in children with optic pathway glioma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T17%3A04%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=68Ga-NOTA-Aca-BBN(7-14)%20PET%20imaging%20of%20GRPR%20in%20children%20with%20optic%20pathway%20glioma&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Zhang,%20Jingjing&rft.date=2019-09-01&rft.volume=46&rft.issue=10&rft.spage=2152&rft.epage=2162&rft.pages=2152-2162&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-019-04392-7&rft_dat=%3Cproquest_cross%3E2251465571%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2251465571&rft_id=info:pmid/&rfr_iscdi=true |